Skip to content
Highlights
– The new Actavis plc is a powerful combination of the highly successful and previously separate Actavis, Inc. (NYSE:ACT) and Warner Chilcott plc (NASDAQ: WCRX)
– Operating as Actavis Pharma, our generic, branded generic, legacy brands and Over-the-Counter (OTC) business markets more than 750 products globally through operations in more than 60 countries.
– Actavis Specialty Brands is a global branded specialty pharmaceutical business focused principally in the Women’s Health, Urology, Gastroenterology and Dermatology therapeutic categories.
– Actavis is committed to developing and marketing biosimilar products in Women’s Health, Oncology and other therapeutic categories.
– Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.
– Actavis develops and out-licenses generic pharmaceutical products to customers in more than 100 countries outside of the U.S. through its Medis third-party business.
×

Deadline extended to July 15th

Problems caused by shortages are serious, threaten patient care and require urgent action.

Help us provide an overview of the scale of the problem, as well as insights into the impact on overall patient care.

Our aim is to investigate the causes of medicine and medical device shortages in the hospital setting,  while also gathering effective solutions and best practices implemented at local, regional, and national levels.

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.